Keyphrases
Acute Myeloid Leukemia
41%
Adhesion Molecules
6%
Adoptive Transfer
18%
Allogeneic Donors
36%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
46%
Autologous HSCT
10%
Autologous Transplantation
36%
CD62L
12%
Cell Culture
12%
Cell Yield
36%
Clinical Outcomes
7%
Complete Response
6%
Cytokine Production
6%
Cytomegalovirus
15%
Enhanced Cytotoxicity
6%
Forkhead Box O1 (FOXO1)
12%
Further Development
6%
Graft-versus-host Disease (GvHD)
8%
Hematopoietic Cell Transplant
12%
Immune Reconstitution
7%
Interleukin-15 (IL-15)
48%
Ki-67
10%
Lymph Node Homing
6%
Lymphoma
17%
Lymphoma Patients
36%
Maintenance Therapy
36%
Metabolic Changes
6%
Multiple Myeloma
42%
Myelodysplastic Syndrome
36%
N-803
36%
Natural Killer Cell Activity
36%
Natural Killer Cell Expansion
36%
Natural Killer Cells
84%
Nicotinamide
36%
Non-Hodgkin Lymphoma
47%
Oxidative Stress
6%
Partial Response
6%
Phase II Trial
36%
Poor Survival
36%
Pretransplant
36%
Refractory Lymphoma
6%
Regulatory T Cells
36%
Relapsed Lymphoma
6%
Relapsed or Refractory Acute Myeloid Leukemia
12%
Remission
36%
Rituximab
6%
Stem Cell Transplantation
36%
Study Support
6%
Superagonist
36%
Treg
36%
Medicine and Dentistry
Acute Graft Versus Host Disease
9%
Acute Myeloid Leukemia
41%
Adoptive Transfer
15%
Adverse Event
9%
Antineoplastic Activity
9%
Autotransplantation
36%
Cancer Therapy
5%
Cell Adhesion Proteins
5%
Cell Expansion
36%
Cell Function
36%
Cell Proliferation
9%
Cell Survival
5%
Cell Therapy
5%
Cell Transplantation
10%
Clinical Trial
5%
Cytokine Production
5%
Cytomegalovirus
20%
Cytotoxicity
14%
Ex Vivo
10%
Exanthem
9%
Forkhead Transcription Factor
5%
Graft Versus Host Reaction
9%
Hematopoietic Cell
37%
Immunological Memory
5%
Inflammatory Cytokine
5%
Injection Site
9%
Interleukin 15
46%
L Selectin
5%
Leukemia
5%
Lymph Node
5%
Lymphocyte
5%
Lymphocyte Proliferation
9%
Maintenance Therapy
36%
Monoclonal Antibody
5%
Multiple Myeloma
41%
Myelodysplastic Syndrome
36%
Myeloid Malignancy
9%
Natural Killer Cell
100%
Nicotinamide
36%
Non-Hodgkin Lymphoma
10%
Oxidative Stress
5%
Patient with Non-Hodgkins Lymphoma
36%
Rituximab
5%
Stem Cell Transplant
36%
Superagonist
36%
Immunology and Microbiology
Acute Graft Versus Host Disease
7%
Antineoplastic Activity
7%
Autologous Hematopoietic Stem Cell Transplantation
36%
Autotransplantation
36%
Cell Adhesion Proteins
5%
Cell Expansion
36%
Cell Function
36%
Cell Proliferation
7%
Cell Survival
5%
Cell Transplantation
34%
Cytokine Production
5%
Cytomegalovirus
20%
Cytotoxicity
12%
Forkhead Transcription Factor
5%
Graft-Versus-Host Disease
7%
Hematopoietic Cell
56%
Immunocompetent Cell
6%
Immunological Memory
5%
Inflammatory Cytokine
5%
Interleukin 15
46%
L-Selectin
5%
Lymph Node
5%
Lymphocyte
8%
Lymphocyte Proliferation
7%
Monoclonal Antibody
5%
Multiple Myeloma
41%
Myeloid
36%
Natural Killer Cell
94%
Overall Survival
6%
Oxidative Stress
5%
Regulatory T Cell
36%
Rituximab
5%
Stem Cell Transplant
36%
